Navigation Links
NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones
Date:5/21/2009

NuSil Technology announced a definitive agreement to acquire the pharmaceutical Antifoam (Simethicone) business from Bluestar Silicones.

Carpinteria, Calif. (Vocus) May 21, 2009 -- NuSil Technology (http://www.nusil.com), a leading formulator and manufacturer of silicone compounds for the healthcare and pharmaceutical industries, announced a definitive agreement to acquire the pharmaceutical Antifoam (Simethicone) business from Bluestar Silicones effective 1-May-2009. As part of the acquisition, NuSil will begin transitioning the manufacturing of seven key Simethicone products used in pharmaceutical applications. Financial details of the transaction were not disclosed.

"The Bluestar Pharmaceutical Simethicone products are a great complement to the current NuSil Simethicone product line. NuSil's 30 years experience working with healthcare-related materials, including silicones for drug delivery systems and long-term implants, provides us with the working regulatory knowledge needed to support the product line for our customers," said Richard Compton, CEO and co-founder of NuSil. "This acquisition, when combined with our ingestible Simethicone product line that we acquired from GE Advanced Materials in 2004, strengthens our position in the pharmaceutical industry as a leading Simethicone supplier with a broad product offering and global distribution capabilities."

Simethicones are wide spectrum antifoam and defoaming products which have been used successfully in various industries including pharmaceutical, food and cosmetics. In the pharmaceutical industry, Simethicones have shown efficacy as antifoams in processes such as biological fermentations and in the manufacture of antibiotics. Simethicones are also widely used as active pharmaceutical ingredients in anti-flatulent formulations. NuSil's current Simethicone products meet various monographs including the European Pharmacopeia for Simethicone and the United States Pharmacopeia for Simethicone Emulsion (contact NuSil for specific references). As part of this acquisition, NuSil will transfer the manufacturing of the Bluestar Silicones Pharmaceutical Simethicone business to NuSil's FDA registered facility in Bakersfield, California.

NuSil formulates standard and customized silicone products based on the vast, unique array of properties the material provides. Product quality is assured by the company's Quality System, which begins with an effective design protocol and continues up the supply chain from vendor qualification through re-inspection of finished product inventories.

For more information on NuSil's silicones for pharmaceuticals, call 805-684-8780 or visit http://www.nusil.com/simethicone.

About NuSil Silicone Technology
NuSil is a leading formulator of silicone compounds for healthcare, aerospace, electronics and other applications requiring precise, predictable materials performance. ISO-9001 certified since 1994, NuSil operates state-of-the-art laboratories and processing facilities in North America and provides on-site, in-person application engineering support worldwide. More information about NuSil Technology can be found at http://www.nusil.com.

Media Contact
Stephanie Supina
NuSil Technology
805-684-8780 x221

# # #

Read the full story at http://www.prweb.com/releases/NuSil/Simethicone/prweb2447954.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC
2. Recondo Technology Announces Two New Board Members
3. Nanotechnology May Simplify Antibiotic Treatment
4. SMS Technology Places Eye Health Educational Information at Hispanics Fingertips
5. NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference
6. Cleveland Clinic CIO Named to Federal Advisory Committee on Health Information Technology
7. Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records
8. Connectyx CEO Announces Support of the Obama Plan to Invest in Health Information Technology
9. NewCardio to Introduce Technology at Heart Rhythm Society Conference
10. Zila & Experts Testify at Congressional Hearing on Innovative Technology for Veterans; Urge Broader Use of ViziLite(R) Plus by VA for Oral Cancer Screening
11. Smart Phone, ePRO, and eDiary Technology Advances for Clinical Trials, Market Research, and Registries Reported by assisTek
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 
(Date:12/5/2016)... Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... concussions have on the growing brains of young athletes. Over the course of three ... the head through unique mouth guards. The mouth guards, equipped with special sensors, will ...
(Date:12/5/2016)... NY (PRWEB) , ... December 05, 2016 , ... ... to use a patent-pending blend of L-Citrulline and glutathione to enhance production of ... a combination that studies have shown to produce NO twice as effectively and ...
(Date:12/5/2016)... ... December 05, 2016 , ... Eating disorders ... goal of Castlewood Treatment Centers has always been to promote the power of ... people as possible. In that spirit, Castlewood has announced two new hires, both ...
(Date:12/5/2016)... ... December 05, 2016 , ... U.S. Apple Association (USApple) ... part of the second annual Apples for Education: Buy an Apple, Help a ... providing healthy food for students to take home to their families; solar technology to ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Partners ("GPP") portfolio company, today announced it has acquired the assets of ... was previously a subsidiary of Chiltern International and focuses on clinical trial ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... India , December 5, 2016 According ... by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free ... published by MarketsandMarkets, the market is projected to reach USD 779.8 ... a CAGR of 13.5% during the forecast period of 2016 to ... ...
(Date:12/5/2016)... and PUNE, India , December 5, ... by Allied Market Research, titled, "Global Cancer Biomarkers Market - ... of cancer biomarkers market is projected to reach $15,737 million ... of 13.3% from 2016 to 2022. Omic technologies segment accounted ... and is expected to maintain its dominance during the forecast ...
(Date:12/5/2016)...  CVS Health, the nation,s largest pharmacy innovation company, ... of 100 percent on the Corporate Equality Index (CEI) ... annual national benchmarking survey and report on corporate policies ... Human Rights Campaign Foundation. "Our company,s ... customers and suppliers bring to CVS Health," said ...
Breaking Medicine Technology: